Apigenin Sensitizes Prostate Cancer Cells to Apo2L/TRAIL by Targeting Adenine Nucleotide Translocase-2

Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapeutic agent. Recombinant human Apo2L/TRAIL has been under clinical trials, whereas various kinds of malignant tumors have resistance to Apo2L/TRAIL. We and others have shown that several a...

Descripción completa

Detalles Bibliográficos
Autores principales: Oishi, Masakatsu, Iizumi, Yosuke, Taniguchi, Tomoyuki, Goi, Wakana, Miki, Tsuneharu, Sakai, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576345/
https://www.ncbi.nlm.nih.gov/pubmed/23431365
http://dx.doi.org/10.1371/journal.pone.0055922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576345/
https://www.ncbi.nlm.nih.gov/pubmed/23431365
http://dx.doi.org/10.1371/journal.pone.0055922

Ejemplares similares